#dna aptamers

[transgenderlabrat]

I will never take having a procedure provided to me for granted again oh my goddd experimental design is hellish.

[bichitosdecolores]

i jus had the funniest interaction

today i participated on my first congress (yei!) and i was standing next to my science-looking poster in a room full of science-looking posters in the middle of the chemistry faculty. so this guy, confidently walking down the hall in a phone call, suddenly stops in front of my poster (the last in a long hall of posters) and ask me what all that is about, to which i answer ”chemistry, biochemistry and stuff like that. He then asks through his phone call “do you want to listen to something on chemistry?” and then after, i suppose a positive answer, he talks to me and asks me to explain my poster. and explain my poster i do. i start talking about aptamers and dna and antibodies like i’ve done a couple times before to all the people (in a chemistry congress) that have asked. i’m like 40 seconds into my explanation when the guy rises his hand and stops me. oh a question, i think, getting ready for it. and then he says “i haven’t understood a thing you say, can you explain it on christian (a way to say “easy terms”)

and then i think, well this is a chemistry congress and a some of people from chemist engineering and pure chemistry have approached before having difficulty understanding the really heavy bio(chemistry) part of my investigation. so this isn’t weird to me. i go back and explain that an antibody is a protein but it sucks for detecting analytes because of denaturalization and blah blah. stuff a biochemist would know by heart but that a pure chemist may not. i’m not even a minute in this new explanation when he stops me again and says he still doesn’t understand, then he says something in what i’m pretty sure was latin and finally reveals he is from the letters and philosophy faculty and got lost and ended up there hshsah.

and he once again asked me to explain it in even simpler terms and i do so (or try) and i end up explaining that antibodies are “lego glue” and influenza is an allergy (??? it’s not!) and enzymes are little boxes that take colors and change them. hshshdba

anyways, best interaction i had all day and now i have his number and i’m friends with a philosopher i think??

[neha24blog]

Aptamers Market Segmented On The Basis Of Type, Application, Technology, End-User, Region And Forecast To 2030: Grand View Research Inc.

Aptamers Market Segmented On The Basis Of Type, Application, Technology, End-User, Region And Forecast To 2030: Grand View Research Inc.

San Francisco, 8 Dec 2022: The Report Aptamers Market Size, Share & Trends Analysis Report By Type (Nucleic Acid (DNA, RNA, XNA), Peptide), By Application (Diagnostics, Therapeutics, Research & Developments, Others), By Technology, by End-user, By Region, And Segment Forecasts, 2022 – 2030 The global aptamers market size is expected to reach USD 10.9 billion by 2030, according to a new report by…

[surbhijamdade]

Revenue Forecast and Competitive Landscape for the Oligonucleotide Synthesis Market

The Oligonucleotide Synthesis Market Report for 2024 provides a comprehensive overview of the Oligonucleotide Synthesis Market industry, presenting crucial data and insights into market dynamics, including growth drivers, challenges, and future potential. The report evaluates the Oligonucleotide Synthesis Market Components, focusing on significant opportunities and trends that could shape the industry's trajectory.

According to Straits Research, the global Oligonucleotide Synthesis Market market size was valued at USD 7.74 billion in 2023. It is projected to reach from USD 8.84 billion in 2024 to USD 25.57 billion by 2032, growing at a CAGR of 14.2% during the forecast period (2024–2032).

Get a Sample PDF/Excel of report starting from USD 995 :https://straitsresearch.com/report/oligonucleotide-synthesis-market/request-sample

Top Key Players of Oligonucleotide Synthesis Market :

Agilent Technologies, Inc.

ATDBio Ltd.

TriLink BioTechnologies LLC

Thermo Fisher Scientific

Nitto Denko Corporation

Merck KGaA

LGC Biosearch Technologies

Integrated DNA Technologies, Inc.

GenScript

GE Healthcare

Eurogentec

Eurofins

and more....

Key Insights from the Oligonucleotide Synthesis Market Report

Market Size Overview: The report provides comprehensive estimates of the Oligonucleotide Synthesis Marketsize, including value and sales volume, for the period.

Market Trends and Dynamics: An analysis of the key drivers, opportunities, challenges, and risks shaping the Oligonucleotide Synthesis Market.

Global Economic and Regional Impact: Evaluation of the effects of global inflation and the Russia-Ukraine conflict on the Oligonucleotide Synthesis Market.

Trade Flow Analysis: Detailed examination of import and export volumes of Oligonucleotide Synthesis Marketacross major regions.

Industry Value Chain: Insight into the Oligonucleotide Synthesis Marketvalue chain, covering raw materials, suppliers, manufacturing processes, distributors, and downstream customers.

Industry News, Policies, and Regulations: Coverage of the latest developments, policies, and regulations impacting the Oligonucleotide Synthesis Market.

Regional Analysis for Oligonucleotide Synthesis Market:

The regional analysis section of the report offers a thorough examination of the global Oligonucleotide Synthesis Market market, detailing the sales growth of various regional and country-level markets. It includes precise volume analysis by country and market size analysis by region for both past and future periods. The report provides an in-depth evaluation of the growth trends and other factors impacting the Oligonucleotide Synthesis Market market in key countries, such as the United States, Canada, Mexico, Germany, France, the United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil, and Saudi Arabia. Moreover, it explores the progress of significant regional markets, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Oligonucleotide Synthesis Market Segmentations:

By Product Type

Synthesized Oligonucleotide Product

Reagents

Equipment

By Applications

Research

PCR

Sequencing

Gene Synthesis

Diagnostics

Therapeutics

RNAi

Nucleic Acid Aptamers

Others

By End-User

Academic Research Institutes

Pharmaceutical and Biotechnology Companies

Diagnostic Laboratories

Others

Get Detail Market Segmentation :https://straitsresearch.com/report/oligonucleotide-synthesis-market/segmentation

Unit Economics must be known by C-suite professionals:

Cost of Goods Sold (COGS): Includes material, labor, and overhead costs in manufacturing.

R&D Costs: Investment in innovation and compliance with regulations.

Engineering and Design Costs: Resources for design, prototyping, and meeting technical standards.

Production Costs: Specialized manufacturing and quality control expenses.

Supply Chain Costs: Managing procurement and logistics for specialized components.

Testing and Quality Assurance: Costs for ensuring product safety and reliability.

SG&A Costs: Marketing, sales, and administrative expenses.

Revenue per Unit: Income from contracts, services, and licensing.

Gross Margin: Revenue minus COGS, showing unit profitability.

Break-even Analysis: Units or contracts needed to cover total costs.

Customer Acquisition Cost (CAC): Costs to secure new contracts.

Lifetime Value (LTV): Total revenue from a customer over time.

Capital Expenditure (CapEx): Investments in facilities and technology.

Economies of Scale: Cost reductions in larger production runs.

Profit Margin: Final profit after all expenses.

Top Reasons to Choose This Report

Access to Comprehensive Insights: Gain access to extensive analysis, research, and data that are often challenging to gather independently. This report provides valuable information, saving you significant time and effort.

Support for Informed Decisions: Enhance your decision-making process with in-depth insights into market trends, consumer behavior, and key industry factors. This report is essential for strategic planning, including investments, product development, and marketing strategies.

Gain a Competitive Edge: Stay competitive by understanding market dynamics and competitor strategies. The report provides detailed insights into competitor performance and market trends, helping you craft effective business strategies.

Cost-Effective Research Solution: Save on research costs by investing in this report, which offers a detailed and comprehensive analysis of the market. This cost-effective option eliminates the need for extensive independent research.

COVID-19 Aftermath and Geopolitical Influences: Russia-Ukraine Conflict and Middle East Crisis

The report explores the multifaceted impact of COVID-19 on the Oligonucleotide Synthesis Market market, covering both direct and indirect effects across global and local levels. It discusses market size, trends, and growth trajectories in the Oligonucleotide Synthesis Market , classified by type, application, and customer sector. Additionally, it provides a detailed evaluation of market development components before and after the pandemic, supported by a PESTEL analysis to assess key influencers and barriers to market entry. We offer the flexibility to customize the report based on specific regions, applications, or any other statistical details. Our goal is to align our analysis with your specific needs, ensuring a more complete market study. The final report will also examine the impact of the Russia-Ukraine War on the Oligonucleotide Synthesis Market market, assessing how these geopolitical events are influencing current market conditions and future opportunities.

This Report is available for purchase on :https://straitsresearch.com/buy-now/oligonucleotide-synthesis-market

About Us:

Straits Research is a leading research and intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & research reports.

Contact Us: email: sales@straitsresearch.com Address: 825 3rd Avenue, New York, NY, USA, 10022 Tel: +1 646 905 0080 (U.S.) +91 8087085354 (India) +44 203 695 0070 (U.K.)

[latestmarketresearchnews]

Aptamers Market - Structure, Size, Trends, Analysis and Outlook 2030

The global aptamers market was valued at USD 1.94 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 24.54% from 2023 to 2030. This rapid growth is being driven by significant advancements in the development, purification, and drug delivery systems for targeting and eliminating harmful cells, which have garnered the attention of researchers. Aptamers possess several competitive advantages over traditional antibodies, including smaller molecular size, lower immunogenicity (reduced immune response), reduced manufacturing costs, and fewer side effects. These benefits are encouraging research and development (R&D) efforts in the creation of new aptamers, fueling market expansion.

Despite considerable research, no highly effective treatments for COVID-19 have been identified, partly due to the virus's extensive genetic mutations. However, biotechnological approaches, including the use of aptamers, hold promise in combating COVID-19 infections. Nucleic acid-based aptamers and peptide aptamers are believed to offer potential therapeutic solutions for the virus, and various government initiatives are supporting the development of novel treatments for COVID-19. For example, in September 2020, the Department of Community & Economic Development awarded USD 320,000 to Aptagen LLC to fund research and development of a novel COVID-19 treatment. This investment reflects the growing recognition of aptamers' potential in addressing unmet medical needs.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Aptamers are also proving valuable in diagnostics. Using SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology, aptamer-based diagnostic kits and assays can develop high-affinity neutralizers and bioprobes for detecting SARS-CoV-2 and other COVID-19 biomarkers. These innovations are expected to further drive market growth. For example, in December 2021, Achiko AG received approval from the Indonesian Ministry of Health for its COVID-19 diagnostic kit, Aptamex. Aptamex is a second-generation, cost-effective diagnostic tool based on DNA aptamer technology, representing an emerging solution in healthcare diagnostics.

Type Segmentation Insights:

The aptamers market is segmented into nucleic acid aptamers and peptide aptamers. In 2022, the nucleic acid aptamers segment dominated the market, holding a 78.19% share, and is expected to exhibit the highest growth during the forecast period. Many companies are actively exploring the therapeutic mechanisms of nucleic acid aptamers for treating various disorders, such as age-related macular degeneration (AMD). For instance, in June 2021, the U.S. Food and Drug Administration (FDA) granted IVERIC BIO (formerly Ophthotech Corporation) a written agreement under the Special Protocol Assessment (SPA) for the design of its phase 3 clinical trial, GATHER2. The trial aims to assess the efficacy of Zimura, a nucleic acid aptamer-based drug, for patients with geographic atrophy (GA) secondary to AMD. This FDA approval is expected to significantly bolster the growth of the nucleic acid aptamer segment.

The peptide aptamer segment is anticipated to experience substantial growth, with a projected CAGR of 22.77% from 2023 to 2030, driven by its broad applications in diagnostics and therapeutics. For instance, in August 2021, scientists from the Engineering Center for Microtechnology and Diagnostics developed an innovative biosensor for multiparametric express testing in the preclinical diagnostics of cardiovascular diseases. This testing uses next-generation biochips, which are based on a peptide aptamer marker system and molecular recognition technology. The researchers designed peptide aptamers using data from the Data Bank and Protein 3D software. The introduction of such advanced products in the market is likely to increase the utilization of peptide aptamers, contributing to the segment's growth.

In summary, the aptamers market is poised for rapid expansion due to the advantages of aptamers in therapeutic and diagnostic applications, advancements in technology, and ongoing R&D efforts. The market's growth is further supported by government initiatives, regulatory approvals, and the increasing use of aptamer-based solutions in areas such as COVID-19 treatment, diagnostics, and the management of other medical conditions.

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[veliterbio]

How Do Oligo Synthesis Companies Drive Improvement in Biotechnology?

By present accurate, customized oligonucleotides that are essential for state-of-the-art research and development, oligo synthesis businesses propel innovation in the biotechnology industry. By providing premium oligos that are right to certain scientific requirements, these businesses encourage developments in gene editing, diagnostics, and pharmaceutical development. Their proficiency in synthesis, along by cutting-edge technologies, opens up novel avenues for study in genetic engineering, molecular diagnostics, and personalized medicine. Over constant enhancement of synthesis methods and expansion of manufacturing, oligo synthesis companies enable scientists to push the limits of biotechnology, subsequent in innovations that revolutionize various industries, with healthcare.

The Purpose of Biotechnology's Oligo Synthesis Companies Companies that specify in oligo synthesis play an acute role in the biotechnology sector by offering specially created oligonucleotides that are vital for a range of scientific and medical applications. These businesses specify in producing brief DNA or RNA orders that are customized to meet the unique necessities of researchers, enabling advances in fields like gene editing, medicine development, and diagnostics. Oligo synthesis firms ease scientific exploration of intricate genetic pathways by providing accurate and reliable oligos, hence propelling innovation in numerous disciplines.

Growth in the Development of Oligonucleotide Drugs

Modern medicine's oligonucleotide drug finding field has shown promise in providing novel paths for targeted therapeutics. Treatment choices for diseases that were thought to be irredeemable are made likely by oligonucleotides, which may exactly target and control gene expression. Examples of these include antisense oligonucleotides, siRNA, and aptamers. Businesses that produce the modified Oligonucleotide Drug Development, known as oligo synthesis businesses, are essential to this procedure. These companies make sure the oligonucleotides fulfill strict quality requirements, enabling researchers to make therapeutic medicines that are both safe and effective.

Knowing How Oligonucleotides Are Manufactured

To guarantee the formation of high-purity oligos, the oligonucleotide manufacturing process involves a number of complex processes. Nucleotide sequences are initial chemically synthesized, then purified and quality-checked to ensure the precision and purity of the finished product. Because even minute contaminants might affect the outcomes, this methodical technique is crucial for applications in together clinical and scientific settings. To safeguard consistent and dependable results, oligonucleotide manufacturing companies utilize cutting-edge technologies and stringent methods to produce oligonucleotides that precisely match the demands of their consumers.

The Belongings of Companies Producing Oligonucleotides on the Sector

Leading biotechnology businesses in the field cover a comprehensive range of applications from elementary research to clinical medication development by their oligonucleotide synthesis operations. These companies not only supply the required oligonucleotides but also make advances in production techniques and synthesis technologies. Over continuous enhancement of oligonucleotide production competence and scalability, these businesses contribute to fulfilling the increasing demand for tailored oligos in the biotech and pharmaceutical industries. They are significant progressors, facilitating the formation of new treatments and diagnostic instruments through their knowledge and creativity.

The Prognosis for Manufacturing Oligonucleotides

The future of oligonucleotide production appears bright as long as there is a rising demand for these molecules. Enhancements in automation, QC, and synthesis chemistry are anticipated to improve production and offer more customization and scalability. In order to guarantee that high-quality oligonucleotides are effortlessly accessible to gratify the changing demands of the biotechnology industry, oligonucleotide manufacturing companieswill continue to play a vital role in supporting research and drug development.

[tamanna31]

Aptamers Market Share, Supply, Sales, Manufacturers, Competitor and Consumption 2023 to 2030

Aptamers Industry Overview

The global aptamers market size was valued at USD 1.94 billion in 2022 and is expected to grow at a compounded annual growth rate (CAGR) of 24.54% from 2023 to 2030.

Recent advancements in the generation, purification, and drug delivery for killing target cells have attracted the attention of many researchers towards aptamers due to the competitive advantages associated with them. Some of the advantages include small molecular size, low immunogenicity, low cost of manufacturing, and lesser side effects compared to antibodies; may fuel the R&D of novel aptamers, thereby driving market growth. Despite significant efforts, there are currently no highly effective treatments available against COVID-19 infections due to a large number of genetic mutations. However, biotechnological approaches appear to be promising in the treatment of COVID-19.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Consequently, nucleic-acid based aptamers & peptide aptamers might be effective against treating COVID-19 infection. Thus, various initiatives are being undertaken by the government to boost the R&D of novel treatment for COVID-19. For instance, in September 2020, the Department of Community & Economic Development awarded a contract of USD 320,000 to Aptagen LLC for the research and development of novel treatment for the COVID-19.

The aptamers based diagnostic kits and assays developed by using SELEX technology have the ability to develop high-affinity neutralizers and bioprobes for monitoring SARS-COV-2 & COVID-19 biomarkers. Therefore, the introduction of diagnostic kits in the market for disease diagnosis is projected to drive market growth. For instance, in December 2021, Achiko AG received approval from the Ministry of Health of the Republic of Indonesia for Aptamex, a COVID-19 diagnostic kit. Aptamex is a second-generation diagnostic kit developed by using DNA aptamer-based technology that is a cost-effective, chemically synthesized, and an emerging diagnostic kit for healthcare.

Aptamers based diagnostic products are the preferred choice among diagnostic and pathology labs for the diagnosis of disease at the cellular level due to their small size, high specificity, selectivity, and efficacy. Thus, increasing prevalence of diseases such as cancer, CVD, and AMD may increase the footfall of patients in labs for the diagnosis of these diseases, consequently, increasing demand for aptamer based diagnostic products. According to Cancer Research UK estimates, around 27.5 million people are expected to be diagnosed with cancer by 2040.

In March 2022, SomaLogic announced the initiation of assaying samples using SomaScan Assay for the European Prospective Investigation into Cancer and Nutrition (EPIC) study by analyzing 210 million protein measurements from 30,000 samples. This will help researchers in predicting cancer by better understanding its nature, which in turn may contribute in market growth by addressing the increased demand.

As of now, Macugen developed by Eyetech Pharmaceuticals, Inc., (currently commercialized by Bausch Health Companies Inc.) is only the U.S. FDA approved (2004) therapeutic aptamer available in the market. It is used for the treatment of age-related muscular degeneration disorder (AMD). Technological advancements in research encourage scientists’ attention towards the development of novel aptamer based therapeutic drugs for the treatment of various diseases. Currently, there are a number of products under different clinical trials including Zimura developed by IVERIC Bio, Inc., for the treatment of patients with drug AMD. Thus, expected approval of this drug may boost the growth of the market over the period.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global structural biology & molecular modeling techniques market size was valued at USD 7.13 billion in 2023 and is projected to grow at a CAGR of 15.4% from 2024 to 2030.

• The global targeted DNA RNA sequencing market size was valued at USD 10.12 billion in 2023 and is projected to grow at a CAGR of 19.4% from 2024 to 2030.

Global Aptamers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the market trends in each of the sub-markets from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the aptamers market on the basis of type, application, and region.

Type Outlook (Revenue, USD Million; 2018 - 2030)

Nucleic Acid Aptamer

Peptide Aptamer

Application Outlook (Revenue, USD Million; 2018 - 2030)

Diagnostics

Therapeutics

Research & Development

Others

Regional Outlook (Revenue, USD Million; 2018 - 2030)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

MEA

South Africa

Saudi Arabia

UAE

Kuwait

Key Companies & Market Share Insights

Major players are adopting strategies such as modification in the existing product, approval of new products, and mergers & acquisitions for product enhancements and regional expansion to attain a greater market share. For instance, in January 2023, Aptamer Group collaborated with BaseCure Therapeutics for the development of Optimer-targeted therapies. Such initiatives can open new avenues of growth for applications of aptamers in therapeutics. Some of the prominent players in the global aptamers market include:

SomaLogic

Aptamer Group

Aptadel Therapeutics

Base Pair Biotechnologies

Noxxon Pharma

Vivonics Inc.

Aptagen, LLC

TriLink Biotechnologies

Altermune LLC

AM Biotechnologies

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[rnomics]

Chemosensors, Vol. 12, Pages 163: Facile Fabrication of Bio-Nanohybrid Electrode with Guanine/Cytosine-Modified Electrochemically Reduced Graphene Oxide Electrode and Its Application in Doxorubicin Analysis

Graphene, known for its outstanding physical and chemical properties, is widely used in various fields, including electronics and biomedicine. Reduced graphene oxide (rGO) is preferred for electrochemical applications due to its enhanced water solubility and dispersion. Electrochemically reduced graphene oxide (ErGO) is particularly advantageous as it can be prepared under mild conditions and simplifies sensor fabrication; however, ErGO-based electrochemical sensors often lack specificity. Bioreceptors like proteins, enzymes, and DNA/#RNA #aptamers are incorporated to provide high specificity. This study introduces a guanine (G)/cytosine (C)-modified ErGO electrode (G/C@ErGO-GCE) for the sensitive electrochemical detection of doxorubicin (DOX) with good selectivity. The G/C mixture acts as a bioreceptor and is anchored on the ErGO-GCE surface via π-π interactions. The G/C@ErGO-GCE was characterized using scanning electron microscopy, contact angle measurement, Raman spectroscopy, and electrochemical methods. The sensor demonstrated excellent dynamic range (DPV: 10 nM to 1 µM, CA: 30 nM to 1.3 µM), sensitivity (DPV: 2.17 µA/µM, CA: 6.79 µA/µM), limit of detection (DPV: 84 nM, CA: 34 nM), and selectivity for DOX detection, highlighting its potential for biomedical applications and pharmacokinetic studies. https://www.mdpi.com/2227-9040/12/8/163?utm_source=dlvr.it&utm_medium=tumblr

[axelknaus]

A full-size, high-density RNA microchip is about the size of a fingernail and can contain up to 780,000 unique RNA sequences, each covering an area of about 14 x 14 μm².

Tadika Kekić

The next generation of RNA chips

Research team achieves breakthrough: chemical synthesis of high-density RNA microarrays now faster and more efficient

An international research team led by the University of Vienna has succeeded in developing a new version of RNA building blocks with higher chemical reactivity and light sensitivity. This can significantly reduce the production time of RNA chips used in biotechnological and medical research. The chemical production of these chips is now twice as fast and seven times more efficient. The results of the research work were recently published in the renowned journal Science Advances.

The emergence and market approval of RNA-based medical products, such as mRNA vaccines during the COVID-19 pandemic, has also brought the RNA molecule into the public eye. RNA (ribonucleic acid) is an information-carrying polymer - a chemical compound made up of similar subunits - but with a far greater structural and functional diversity than DNA. About 40 years ago, a method for the chemical synthesis of DNA and RNA was developed in which any sequence can be assembled from DNA or RNA building blocks using phosphoramidite chemistry. A nucleic acid chain is built up step by step using these special chemical building blocks (phosphoramidites). Each building block carries chemical "protective groups" that prevent unwanted reactions and ensure the formation of a natural link in the nucleic acid chain.

Mastering challenges

This chemical method is also used in the production of microchips ("microarrays"), where millions of unique sequences can be synthesized and analyzed simultaneously on a solid surface the size of a fingernail. While DNA microarrays are already widely used, adapting the technology to RNA microarrays has proven difficult due to the lower stability of RNA.

Back in 2018, the University of Vienna demonstrated how high-density RNA chips can be produced using photolithography: By precisely positioning a beam of light, areas on the surface can be prepared for the attachment of the next building block through a photochemical reaction. Although this first report was a world first and remains unchallenged to this day, the method suffered from its long production time, low yield and low stability. Now this approach has been massively improved.

Development of a new generation of RNA building blocks

A team from the Institute of Inorganic Chemistry at the University of Vienna, in collaboration with the Max Mousseron Institute for Biomolecules at the University of Montpellier (France), has now developed a new version of RNA building blocks with higher chemical reactivity and light sensitivity. This advance significantly shortens the production time of RNA chips and makes synthesis twice as fast and seven times more efficient. The innovative RNA chips are capable of screening millions of RNA candidates for valuable sequences for a wide range of applications.

"The production of RNA microarrays with functional RNA molecules was simply out of reach with our previous setup. With the improved method using the propionyloxymethyl (PrOM) group as a protecting group, it is now possible," says Jory Lietard, Assistant Professor at the Institute of Inorganic Chemistry.

As a direct application of these improved RNA chips, the publication includes a study of RNA aptamers, small oligonucleotides that bind specifically to a target molecule. Two "glowing" aptamers were selected that produce fluorescence when binding to a dye, and thousands of variants of these aptamers were synthesized on the chip. A single binding experiment is sufficient to obtain data on all variants simultaneously, paving the way for the identification of improved aptamers with better diagnostic properties.

"High-quality RNA chips could be particularly valuable in the rapidly growing field of non-invasive molecular diagnostics. New and improved RNA aptamers are desperately sought, e.g. those that can track hormone levels in real time or monitor other biological markers directly from sweat or saliva," says Tadija Kekić, PhD student in Jory Lietard's group.

This work was financially supported by a joint grant from the Agence Nationale pour la Recherche/Austrian Science Fund (FWF Individual Project International I4923).

Original publication:

Publication in "Science Advances" T. Kekić, N. Milisavljević, J. Troussier, A. Tahir, F. Debart and J. Lietard: Accelerated, high quality photolithographic synthesis of RNA microarrays in situ https://www.science.org/doi/10.1126/sciadv.ado6762 doi: 10.1126/sciadv.ado6762

[healthcaremarketanalysis]

Global Aptamers Market Size Worth USD 342 million by 2026|

The global aptamers market in terms of revenue was estimated to be worth $151 million in 2021 and is poised to reach $342 million by 2026, growing at a CAGR of 17.7% from 2021 to 2026. 

Download PDF Brochure:

Key Market Players:

Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc., (US), Aptamer Sciences, Inc. (South Korea), Aptagen, LLC (US), Maravai Lifesciences (US), Kaneka Corporation (Japan), NeoVentures Biotechnology Inc. (Canada), Aptus Biotech (Spain), Base Pair Biotechnologies (US), AMSBIO (UK), Novaptech (France), Bio-Techne (US)

Browse in-depth TOC on "DNA Aptamers Industry"

196 – Tables

38 – Figures

183 – Pages

Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics.

Lower production cost and higher stability will drive the DNA-based aptamers segment growth

Based on type, the aptamers market is segmented into DNA aptamers, XNA aptamers, and RNA aptamers. The DNA-based aptamers segment dominated the market in 2020. The large share of this segment is attributed to their lower production cost and higher stability compared to other nucleic acid-based aptamers and the wide availability of DNA aptamers.

Request Free Sample Pages:

The therapeutics development segment will continue to dominate the aptamers market during the forecast period

Based on the application, the market is segmented into therapeutics development, research & development, diagnostics, and other applications. The therapeutics development segment dominated the market due to the increasing number of clinical trials evaluating aptamers for new therapies and collaborations among aptamer companies & prominent pharmaceutical and biotechnology firms. The diagnostic segment is projected to grow at the highest CAGR due to the increasing prevalence of chronic diseases and the development of new diagnostic kits to detect cancer and other diseases.

Pharmaceutical & biotechnology companies are the largest end users of aptamers market

Based on end user, the market is segmented into pharmaceutical companies & biotechnology companies, academic & government research institutes, contract research organizations, and other end users. Pharmaceutical & biotechnology companies dominated the market owing to the increasing number of market players offering custom aptamers for use in therapeutics development & rising R&D expenditure. The diagnostic segment will record the highest CAGR during the forecast period due to the development of diagnostic tools for cancer and infectious diseases.

Others segment is expected to witness the highest CAGR during the forecast period

Based on technology, the aptamers market is segmented into SELEX and other technologies. The SELEX technology segment dominated the market in 2020. The segment accounts for a large share of the aptamers market as SELEX is one of the most widely used technologies. The other technologies segment is expected to register the highest CAGR during the forecast period due to the increasing focus on developing technologies for aptamer selection.

North America was the largest regional market for aptamers market in 2020

The global aptamers market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the market. The largest share of North America is attributed to the availability of funds to develop innovative technologies, the presence of prominent market players, and growing collaborations among companies.

Hypothetic Challenges of Aptamers Market in Near Future:

Increased Competition: With the growing popularity of aptamers, more companies are entering the market and competing for market share. This could lead to increased competition and price wars, which could make it difficult for existing companies to remain profitable.

Regulatory Uncertainty: With the technology being relatively new, regulatory frameworks for aptamers are not yet established in many countries. This could lead to uncertainty in the market and could prevent companies from being able to make long-term plans.

Technological Limitations: The current technology behind aptamers is limited in terms of its capabilities. This could lead to a lack of innovation and progress in the market, which could hinder its potential growth.

Cost of Production: The cost of producing aptamers is relatively high due to the complexity of the technology. This could make it difficult for companies to remain competitive and profitable.

Safety Concerns: As with any medical technology, there are always safety concerns surrounding the use of aptamers. This could lead to increased scrutiny and potential legal issues, which could further complicate the market.

Top 3 Use Cases of Aptamers Market:

Diagnostics: Aptamers can be used in various diagnostic applications, such as antigen-antibody assays, DNA/RNA detection, and enzyme assays. Aptamers can also be used to detect drug residues in food and water.

Therapeutics: Aptamers can be used as therapeutic agents to target specific cells and tissues, as well as to deliver drugs directly to their site of action. They can also be used as molecular “scissors” to cleave specific proteins or DNA sequences.

Research: Aptamers are widely used in research applications such as protein structure determination, gene expression profiling, protein-protein interaction studies, and gene silencing. They are also used to study cellular processes such as apoptosis and cell-signalling pathways.

Recent Developments

In August 2021, Aptamer Group, Ltd. and BizCom Japan, Inc. entered into a distribution and marketing agreement to market Optimer discovery and development services in Japan.

In August 2021, Aptamer Group entered a partnership with ProAxsis Limited. As per the partnership, Aptamer Group will develop validated Optimer ligands against critical targets for ProAxsis’s diagnostic assays

In July 2021, Aptamer Sciences, Inc. was selected by the Korean government to support a non-clinical project for a new drug development project for COVID-19 treatment and vaccine and will receive a research grant of about USD 0.51 million for one year through this project.

Get 10% Free Customization on this Report:

[transgenderlabrat]

I officially have an access card for the lab I’m working in!! It’s so fancy!!! I’m a real professional!!!! I have a lab access card!!!

[bichitosdecolores]

hello science comunity of tumblr i need your help.

does anyone know of a free tutorial / youtube series / book or anything like that about molecular docking between ssDNA (specifically, an aptamer) and proteins?

it would be very helpfull if it also includes how to obtain and optimize the tridimentional structure of the DNA molecule

for reference i know pretty much nothing of molecular docking as a whole so anything would be really appreciated

thank you :3

[gis56]

"Aptamers vs. Antibodies: The New Frontier in Biotechnology"

Aptamers, short single-stranded DNA or RNA molecules that can bind to specific targets with high affinity and specificity, are emerging as powerful tools in biotechnology and medicine. These versatile molecules are increasingly used in a wide range of applications, including diagnostics, therapeutics, and drug delivery systems. Aptamers offer several advantages over traditional antibodies, such as easier synthesis, lower immunogenicity, and the ability to be chemically modified for enhanced stability and functionality. Technological advancements in SELEX (Systematic Evolution of Ligands by EXponential enrichment) and high-throughput sequencing are accelerating the discovery and optimization of aptamers, enabling more rapid development of targeted treatments and precision diagnostics. The growing interest in personalized medicine and targeted therapies is driving the adoption of aptamers in clinical research and pharmaceutical development. However, challenges such as the need for robust in vivo stability and efficient delivery methods remain. Despite these hurdles, the future of aptamers is bright, with ongoing research and development poised to unlock their full potential in revolutionizing healthcare.

#Aptamers #Biotechnology #Diagnostics #Therapeutics #DrugDelivery #PrecisionMedicine #SELEX #TargetedTherapies #PersonalizedMedicine #HealthcareInnovation #BiotechResearch #ClinicalResearch #PharmaTech #MolecularBiology #MedicalAdvancements

[simranmakhija1]

Addressing Challenges in Oligonucleotide Synthesis: Quality, Scale, and Efficiency

The Oligonucleotide Synthesis Market is experiencing rapid growth driven by advancements in genomics, personalized medicine, and molecular diagnostics. Oligonucleotides, short sequences of nucleotides, are essential tools in various applications, including DNA sequencing, gene editing, PCR amplification, and RNA interference. The increasing demand for custom oligonucleotides for research, diagnostic, and therapeutic purposes is fueling the expansion of the oligonucleotide synthesis market.

Get a free Sample: https://www.marketdigits.com/request/sample/4550 

One of the key drivers of market growth is the rising adoption of oligonucleotide-based therapies, such as antisense oligonucleotides (ASOs), siRNAs, and aptamers, for the treatment of genetic disorders, cancer, and infectious diseases. Oligonucleotide therapeutics offer targeted and specific modes of action, allowing for precision medicine approaches and reduced off-target effects compared to traditional small molecule drugs. As a result, pharmaceutical companies and biotech firms are investing heavily in oligonucleotide drug discovery and development, driving the demand for high-quality oligonucleotide synthesis services.

The Oligonucleotide Synthesis Market is Valued USD 8.4 billion in 2024 and projected to reach USD 22.9 billion by 2030, growing at a CAGR of CAGR of 15.5% During the Forecast period of 2024-2032.

In addition to therapeutics, oligonucleotides are widely used in research and diagnostics for studying gene expression, identifying genetic mutations, and detecting infectious agents. The growing demand for personalized medicine and companion diagnostics is driving the need for custom oligonucleotide probes and primers tailored to individual patient profiles. Furthermore, advancements in next-generation sequencing (NGS) technologies and gene editing tools, such as CRISPR-Cas9, are driving the demand for high-throughput oligonucleotide synthesis platforms capable of producing large quantities of oligos with high purity and fidelity.

Major vendors in the global Oligonucleotide Synthesis market are Agilent Technologies, Inc., Biolegio, Biolytic Lab Performance Inc., Bio-Synthesis Inc., Cytiva, DH Life Sciences, LLC., GENERI BIOTECH, Horizon Discovery Ltd., Kaneka Eurogentec S.A, LGC Limited, Maravai LifeSciences, Thermo Fisher Scientific Inc., Twist Bioscience.,  and Others.

The oligonucleotide synthesis market is characterized by the presence of both established players and emerging startups offering a wide range of synthesis platforms and services. Major players in the market include Integrated DNA Technologies, Inc. (IDT), Merck KGaA, Thermo Fisher Scientific Inc., Eurofins Scientific SE, and Bio-Synthesis, Inc., among others. These companies provide custom oligonucleotide synthesis services, as well as a variety of oligo modifications, purification methods, and quality control assays to meet the diverse needs of researchers and clinicians.

Emerging trends in the oligonucleotide synthesis market include the development of novel synthesis chemistries, automation technologies, and digital solutions for designing and ordering custom oligos. Continuous innovation in oligonucleotide synthesis platforms, such as microarray-based synthesis, solid-phase synthesis, and enzymatic synthesis, is driving improvements in oligo yield, length, and quality, enabling new applications in synthetic biology, nanotechnology, and drug delivery.

Looking ahead, the oligonucleotide synthesis market is poised for further expansion driven by advancements in gene therapy, nucleic acid-based vaccines, and precision diagnostics. As the field of genomics continues to evolve, the demand for custom oligonucleotide synthesis services will continue to grow, offering new opportunities for market players to innovate and collaborate in addressing unmet needs in healthcare and life sciences research.

[veliterbio]

What Makes an RNA Synthesis Company Vital for Biotech Innovation?

The tailored RNA molecules obligatory for cutting-edge investigation and pharmaceutical development are provided by RNA synthesis businesses, which are energetic for biotech innovation. These businesses have the expertise to generate customized RNA oligonucleotides, which are vital for RNA interference, gene therapy, and vaccine development. These companies help researchers to follow novel directions in genetics and generate groundbreaking therapies by assuring accurate and good RNA production. They are vital collaborators in the advancement of biotechnology since of their capacity to create customized RNA sequences, which speeds up the development and application of novel biotechnologies.

The Biotechnology of RNA Oligo Synthesis: Its Significance An essential biotechnology process that lays the groundwork for a diversity of scientific and medical applications is RNA oligo production. Investigators can study gene function, control gene expression, and make new treatments by using RNA oligonucleotides, which are small sequences of RNA that are generated to meet specific necessities. For approaches like gene editing, mRNA vaccinations, and RNA interference (RNAi), where exact RNA sequences are required to produce the desired consequences, RNA oligo production is vital. To advance these fields and spur biotechnology innovation, it is important to be able to generate bespoke RNA oligos by great precision and purity.

Research and Development: The Function of an RNA Synthesis Company

In the study and creation of cutting-edge biotechnologies, an RNA synthesis company is essential. These businesses provide specialized RNA oligonucleotide manufacturing services, giving researchers the resources they require to conduct studies and create novel therapeutic interventions. Scientists can conduct tests with confidence in the correctness and dependability of their materials when an RNA synthesis firm provides them with high-quality, customized RNA sequences. Gene treatments, vaccinations, and other RNA-based technologies that are revolutionizing the biotechnology industry depend on this assistance to advance.

Modern Medicine's Reaction to Oligonucleotide Drugs

Therapeutics recognized as oligonucleotide medicines are a fast expanding class that offer novel approaches to giving a range of illnesses. These medications, which include aptamers, siRNA, and antisense oligonucleotides, function by exactly modifying and targeting certain gene expression. Treatments for viral infections, malignancies, and genetic diseases have all showed promise by oligonucleotide medicines. Custom oligonucleotide synthesis is a precarious component of drug research since it proposals the RNA or DNA sequences required for therapeutic design and testing.

The Technique of Manufacturing Drug Substances for Oligonucleotides

To promise the creation of safe and effective therapeutic agents, the drug substance manufacturing procedure for oligonucleotides is intricate and deeply controlled. The oligonucleotide drug material is synthesized in this technique, and then it is cleansed, formulated, and subjected to severe quality control testing. Strict regulatory necessities must be encountered during the manufacturing procedure to guarantee that the finished product is pure, consistent, and suitable for clinical usage. In order to safeguard that these cutting-edge treatments fulfill the vital standards for quality and safety, businesses that specialize in the production of oligonucleotide drug substances are vital to their commercialization.

The Use of Personalized Oligonucleotide Synthesis in the Development of Therapeutics

Particularly for disorders where there are specific genetic targets, custom oligonucleotide synthesis is precious in the creation of novel therapeutics. Through this method, oligonucleotides that are specifically tailored to meet the necessities of each therapeutic application can be designed and produced. The precise RNA or DNA sequences needed for experimental medications must be created via custom synthesis in order for researchers to evaluate and improve their treatment strategies. Personalized medicine and other cutting-edge therapeutic approaches are made possible by the flexibility and accuracy provided by custom oligonucleotide synthesis in the development of targeted medicines.